PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
1.30M / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-100.00%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-100.00%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-100.00%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-100.00%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-100.00%
Negative net income growth while XRF.AX stands at 13.78%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-100.00%
Negative EPS growth while XRF.AX is at 12.54%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-100.00%
Negative diluted EPS growth while XRF.AX is at 12.54%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-100.00%
Share reduction while XRF.AX is at 1.21%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 10Y revenue/share CAGR while XRF.AX stands at 151.40%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
10Y OCF/share CAGR at 75-90% of XRF.AX's 132.15%. Bill Ackman would demand strategic changes to close the gap in long-term cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 10Y net income/share CAGR while XRF.AX is at 198.79%. Joel Greenblatt sees a major red flag in long-term profit erosion.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Our R&D shrinks while XRF.AX invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-100.00%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.